|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
|
BRPI0915282A2
(pt)
|
2008-06-17 |
2017-02-07 |
Univ Indiana Res & Tech Corp |
agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
|
|
RU2578591C2
(ru)
|
2008-12-19 |
2016-03-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Лекарственные средства, связанные с дипептидами
|
|
AR074811A1
(es)
|
2008-12-19 |
2011-02-16 |
Univ Indiana Res & Tech Corp |
Profarmaco de peptido de la superfamilia de glucagon basados en amida
|
|
US9150632B2
(en)
|
2009-06-16 |
2015-10-06 |
Indiana University Research And Technology Corporation |
GIP receptor-active glucagon compounds
|
|
HUE027229T2
(en)
|
2009-12-16 |
2016-08-29 |
Novo Nordisk As |
Double acylated glp-1 derivatives
|
|
EP2588127A4
(en)
|
2010-06-24 |
2014-06-11 |
Univ Indiana Res & Tech Corp |
DIPEPTIDE-NETWORKED MEDICAL ACTIVE SUBSTANCES
|
|
CA2796894A1
(en)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
HRP20180425T1
(hr)
|
2010-12-16 |
2018-04-20 |
Novo Nordisk A/S |
Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
|
|
US8975223B2
(en)
|
2010-12-22 |
2015-03-10 |
Marcadia Biotech, Inc. |
Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146
|
|
WO2012088116A2
(en)
|
2010-12-22 |
2012-06-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
|
JP5914641B2
(ja)
|
2011-06-10 |
2016-05-11 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用
|
|
US8859491B2
(en)
*
|
2011-11-17 |
2014-10-14 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
|
WO2013139695A1
(en)
|
2012-03-22 |
2013-09-26 |
Novo Nordisk A/S |
Compositions comprising a delivery agent and preparation thereof
|
|
IN2014MN02304A
(enExample)
|
2012-05-03 |
2015-08-07 |
Zealand Pharma As |
|
|
JP6517690B2
(ja)
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー／エス |
ペプチド及び送達剤を含む錠剤製剤
|
|
PL2864350T3
(pl)
|
2012-06-21 |
2019-01-31 |
Indiana University Research And Technology Corporation |
Analogi glukagonu wykazujące aktywność wobec receptora GIP
|
|
SG10201705097PA
(en)
|
2012-12-21 |
2017-07-28 |
Sanofi Sa |
Functionalized exendin-4 derivatives
|
|
US20160058881A1
(en)
|
2013-03-15 |
2016-03-03 |
Indiana University Research And Technology Corporation |
Prodrugs with prolonged action
|
|
ES2688462T3
(es)
|
2013-05-02 |
2018-11-02 |
Novo Nordisk A/S |
Dosificación oral de compuestos de GLP-1
|
|
WO2014192284A1
(en)
|
2013-05-28 |
2014-12-04 |
Takeda Pharmaceutical Company Limited |
Peptide compound
|
|
WO2015022420A1
(en)
|
2013-08-16 |
2015-02-19 |
Medimmune Limited |
Gip and glp-1 receptor dual-agonists for the treatment of diabetes
|
|
WO2015035419A1
(en)
|
2013-09-09 |
2015-03-12 |
Hoffmann-La Roche Inc. |
Dosages of gip/glp-1 co-agonist peptides for human administration
|
|
CN105849122B
(zh)
|
2013-11-06 |
2021-04-30 |
西兰制药公司 |
Gip-glp-1双重激动剂化合物及方法
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
GB2528436A
(en)
|
2014-07-15 |
2016-01-27 |
Lancaster Univ Business Entpr Ltd |
Treatment of neurological diseases
|
|
JP6701208B2
(ja)
|
2014-09-24 |
2020-05-27 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
脂質化アミド系インスリンプロドラッグ
|
|
WO2016077220A1
(en)
|
2014-11-10 |
2016-05-19 |
Mb2 Llc |
Gip/glp-1 co-agonist peptides for human administration
|
|
JP2018012644A
(ja)
|
2014-11-26 |
2018-01-25 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
JOP20200119A1
(ar)
*
|
2015-01-09 |
2017-06-16 |
Lilly Co Eli |
مركبات مساعد مشترك من gip وglp-1
|
|
WO2016131893A1
(en)
|
2015-02-18 |
2016-08-25 |
Medimmune Limited |
Incretin fusion polypeptides
|
|
US20170112897A1
(en)
|
2015-10-23 |
2017-04-27 |
Cedars-Sinai Medical Center |
Methods for treating brain insulin resistance
|
|
US10501516B2
(en)
|
2016-05-24 |
2019-12-10 |
Takeda Pharmaceutical Company Limited |
Peptide compound
|
|
GB201620611D0
(en)
|
2016-12-05 |
2017-01-18 |
Univ Of Lancaster |
Treatment of neurological diseases
|
|
JOP20180028A1
(ar)
|
2017-03-31 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركب ببتيد
|
|
EP3746111B1
(en)
|
2018-02-02 |
2023-07-19 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
|
|
AU2019263674B2
(en)
|
2018-05-04 |
2023-03-02 |
Novo Nordisk A/S |
GIP derivatives and uses thereof
|
|
UA128697C2
(uk)
|
2018-07-23 |
2024-10-02 |
Елі Ліллі Енд Компані |
Способи застосування коагоніста gip/glp-1 для терапії
|
|
CN112469431A
(zh)
|
2018-07-23 |
2021-03-09 |
伊莱利利公司 |
使用gip/glp1共激动剂用于糖尿病的方法
|
|
TW202523681A
(zh)
|
2018-07-23 |
2025-06-16 |
美商美國禮來大藥廠 |
Gip/glp1共促效劑化合物
|
|
CN112351994B
(zh)
*
|
2019-04-11 |
2024-06-07 |
江苏豪森药业集团有限公司 |
一种多受体激动剂及其医药用途
|
|
CN110642935A
(zh)
|
2019-09-25 |
2020-01-03 |
成都奥达生物科技有限公司 |
一种替瑞帕肽类似物
|
|
CN110684082B
(zh)
|
2019-10-08 |
2021-12-10 |
江苏诺泰澳赛诺生物制药股份有限公司 |
Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
|
|
BR112023000270A2
(pt)
|
2020-07-22 |
2023-01-31 |
Novo Nordisk As |
Composto, composição farmacêutica, e, peptídeo
|